Study on the Mechanism of Sophora tonkinensis in the Treatment of Leukemia Based on Network Pharmacology / 中国药房

ABSTRACT

OBJECTIVE： To investigate the potential mechanism of Sophora tonkinensis in the treatment of leukemia. METHODS： The active components and their target proteins of S. tonkinensis were searched by the analysis of traditional Chinese medicine system pharmacology platform， and UniProt database and PubMed database were used to query corresponding gene names of target proteins of active components. Cytoscape 3.6.0 software was used to construct compound-target network. The genes related to leukemia were searched by DisGeNET databases， and OmicShare platform was used to screen the intersection genes of the active component targets of S. tonkinensis and leukemia disease targets. STRING database and Cytoscape 3.6.0 software were used to construct PPI network， and topological analysis was performed. GO analysis and KEGG pathway enrichment analysis were performed by using DAVID bioinformatics database. RESULTS： There were 13 active components and 204 target proteins in S. tonkinensis. The components and targets with high node degree included quercetin， kaempferol， PTGS2， PRSS1， CAMKK2， etc. There were 24 intersection genes between the active component target and leukemia target， including IRF1， BCL2， CYP1A1， PIM1， etc. PPI network of the above intersection genes contained 24 nodes and 142 edges， with an average node degree of 6.5 and an average medium of 0.045. The results of GO analysis showed that the biological process of the above-mentioned genes involved in apoptosis signaling pathway in vitro without ligands， negative regulation of apoptosis process， positive regulation of B cell proliferation， etc. Molecule function mainly included that protein homology activity and binding of the same protein. Cell components mainly included extracellular region， mitochondria and so on. KEGG pathway enrichment showed that above-mentioned genes were mainly associated with T cell receptor signaling pathway， JAK/STAT signaling pathway， HTLV-Ⅰ infection. CONCLUSIONS： Through JAK/STAT signaling pathway and HTLV-Ⅰ infection pathway， the active components of S. tonkinensis may act on PTGS2， PRSS1， CAMKK2 and other targets， and then play a therapeutic role on leukemia， showing the characteristics of multi-component， multi-target and multi-channel.